ADVERTISEMENT
News
Purchase Agreement for Regenerative Tech Company Reached
01/26/2018
Alliqua BioMedical Inc (Yardley, PA) reached a definitive agreement with Celularity, Inc (Warren, NJ), in which Celularity will acquire all of the intellectual property, assets, and rights from the advanced biologic wound care business. Valued at $29 million, the deal was unanimously approved by Alliqua’s board of directors. The asset purchase agreement includes the Biovance amniotic membrane allograft, Interfyl human connective tissue matrix, UltraMist therapy system, and other therapeutic ultrasound products, but it does not include Alliqua’s contract manufacturing assets and operations.
Visit https://alliqua.com/ for more information.
Advertisement
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
Advertisement
Coping With COVID-19
Advertisement